The meeting will be held on 15 of September in L’ Aquila
The aim of the meeting will be gathering a group of world-class scientists that thanks to lectures and open audience panels will offer a unique opportunity of presentation of high quality science along with creating a chance of fruitful networking
Therefore, on this premise, all the meeting is designed for leaving the floor to game-changer preclinical and clinical scientists showing how the integration of these two approaches can be of mutual benefit for cancer patients
In particular, the translational impact and the perspectives unraveled by the studies on genetics, cell cycle, proliferation, and metabolisms, immune response and microbiome will be discussed into deep
The meeting will be also focused on the current clinical trials and how to underpin their actual impact thanks to the solidity of the rationale on which they are designed and the methods to assess their clinical outcome (i.e end points, patients selection, control groups, fragility index censoring etc)
ACCREDITATO PER: medico chirurgo; biologo, TSLB
